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       Dendritic cells (DCs) and macrophages 
(MFs) are important multifunctional immune 
cells. Like other cell types, they express 
hundreds of different miRNAs that are 
recently discovered post-transcriptional 
regulators of gene expression. Here we present 
updated miRNA expression profiles of 
monocytes (MOs), DCs and MFs. Compared to 
MOs, about 50 miRNAs were found to be 
differentially expressed in immature and 
mature DCs or MFs, with major expression 
changes occurring during the differentiation. 
Knock-down of DICER1, a protein needed for 
miRNA biosynthesis, led to lower DC-specific 
intercellular adhesion molecule-3-grabbing 
non-integrin (DC-SIGN) and enhanced CD14 
protein levels confirming the importance of 
miRNAs in DC differentiation in general. 
Inhibition of the two most highly up-regulated 
miRNAs, miR-511 and miR-99b, also resulted 
in reduced DC-SIGN level. Prediction of 
miRNA-511 targets revealed number of genes 
with known immune functions, of which TLR4 
and CD80 were validated using inhibition of 
miR-511 in DCs and luciferase assays in 
HEK293 cells. Interestingly, under the cell 
cycle arrest conditions, miR-511 seems to 
function as positive regulator of TLR4. In 
conclusion, we have identified miR-511 as a 
novel potent modulator of human immune 
response. In addition, our data highlight that 
miRNA influence on gene expression is 
dependant on the cellular environment.  
 
Dendritic cells (DCs) and macrophages 
(MFs) are important immune cells both capable 
of pathogen recognition, phagocytosis, antigen 
presentation and cytokine production. However, 
DCs are more specialized for the presentation of 
antigens and therefore they have the ability to 
migrate from tissues to local lymph nodes where 
they interact with T cells (1, 2). Compared to 
DCs, MFs act more locally and are considered the 
main phagocytic cells, which remove pathogens 
and cell debris that is generated either during 
tissue remodeling associated with apoptosis or 
during inflammation (1, 3).  
In human peripheral blood, DCs represent 
only about 0.5% of leukocytes. However, DCs 
and MFs are relatively easy to differentiate ex 
vivo from human blood monocytes (MOs), which 
represent about 10% of human blood 
mononuclear cells (4, 5). Depending on locations 
and progenitors, there exist many different DC 
and MF populations. Ex vivo, in the presence of 
Granulocyte macrophage colony-stimulating 
factor (GM-GSF) and IL4 or GM-CSF only, 
human blood MOs differentiate into the cells 
which resemble inflammatory DCs or classically 
activated MFs and possess MHCII+DC-
SIGN(CD209)+CD14− and MHCII−DC-
SIGN−CD14+ phenotypes, respectively. After 
stimulation through pathogen recognition 
receptors, such as toll-like receptors (TLRs), they 
achieve activated characteristics and produce 
higher levels of CD86, CD83 and pro-
inflammatory cytokines. Remarkably, the ex vivo 
differentiated DCs are efficient in stimulation of 
CD4 and CD8 positive T cells and are also the 
most common type of DCs used in 
immunotherapeutic approaches (6, 7).  
MicroRNAs (miRNAs) are 21-23 nt long 
single-stranded RNAs, which together with 
partner proteins mainly cause gene silencing by 
degradation of target mRNAs or inhibition of 
translation (8-11). However, upon cell cycle 
arrest, miRNAs can up-regulate the translation as 
it was first shown for miR-369-3, which functions 
as positive regulator of the TNF-α protein 
response to quiescence (12, 13).  
Several miRNAs have been shown to be 
important in differentiation and functioning of 
immune cells (14, 15). For instance, miR-146 has 
been confirmed to regulate inflammatory 
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responses in several different cell types (16-18) 
and is implicated in the multiple cancers and 
inflammatory diseases (14, 19). The other well 
studied miRNA in immune cells is miR-155, 
which is required for normal function of mouse 
DCs, MFs, B and T cells (20-22). In DCs and 
MFs, miR-155 is up-regulated during maturation 
and influences both the differentiation and 
immune responses (23-26). More recently, miR-
34 and miR-21 were shown to be important for 
human MO derived DC differentiation by 
targeting the mRNAs encoding Jagged1 and 
WNT1 (27). miR-21 also targets PDCD4 and 
thereby acts  as negative regulator of TLR4 in 
mouse MFs (28). In addition, several other 
miRNAs are involved in regulation of 
components of the TLR signalling system (29). 
Based on early releases of miRBase, the 
expression profiles of miRNAs in human blood 
MOs, DCs and MFs have been determined (23, 
27, 30). However, the expression and roles of 
more recently discovered miRNAs in DCs and 
MFs are not described. The aim of this study was 
to find novel miRNAs important in MO derived 
DC and MF differentiation and functions. 
Consistent with the previous studies, we found 
that MOs, DCs and MFs have distinct miRNA 
expression profiles, whereas the major changes in 
miRNA expression occured during differentiation 
of MFs and DCs. The most highly up-regulated 
miRNAs were subjected to further studies, which 
point to the role of miR-511 in DC 
differentiation, and importantly, in the regulation 
of the TLR4 protein level.  
 
 
EXPERIMENTAL PROCEDURES 
 
Differentiation of DCs and MF. This study on 
human blood derived MOs is approved (Approval 
166/T-10) by Ethics Review Committee on 
Human Research of the University of Tartu. All 
human participants gave written informed 
consent. Human MOs and MO derived DCs and 
MFs were essentially prepared according to (4) 
and as described.  MOs were purified from 
freshly collected “buffy coats” obtained from 
Blood Centre of Tartu University Hospital. 
PBMCs were prepared by density gradient 
centrifugation on Ficoll-PaqueTM PLUS (GE 
Healthcare) and MOs were further purified by 
positive sorting using anti-CD14-conjugated 
magnetic microbeads using two runs through LS 
columns (both from Miltenyi Biotech). MOs were 
differentiated into MFs using 50 ng/ml GM-CSF 
and into DCs using 50 ng/ml GM-CSF and 25 
ng/ml IL-4 (both from PeproTech) by growing 6 
days at concentration of 1 million cells/ml in 
RPMI 1640 supplemented with 2 mM L-
glutamine, 100 U/ml penicillin, 100 μg/ml 
streptomycin and 10% FCS (all from PAA). For 
maturation, 1 µg/ml of Lipopolysaccharide (LPS, 
InvivoGen) or 0.1 mg/ml of curdlan (Wake 
Chemicals) was added to the growing media for 
24 hours.  
Transfection of anti-miR inhibitors and 
siRNAs. Pre-designed anti-miRNA inhibitors, 
Silencer Select Validated DICER1 siRNAs 
s23754, s23756 and respective negative controls 
(Applied Biosystems) were used in Fig. 2. LNA 
based miR-511 inhibitor and unlabeled control A 
(Exiqon) in Fig. 3 and Fig. S5. All transfections 
were carried out at the concentration of 120 nM 
siRNA or miRNA inhibitors using 3 µl of 
siPORT NeoFX Transfection agent for 106 cells/1 
ml medium (Applied Biosystems). After the 
transfection procedure, MOs were differentiated 
as usual. Transfection efficiency was controlled 
by fluorescence microscopy of separate 
transfections by Cy3 labeled negative control 
miRNA inhibitor or negative control siRNAs and 
was estimated to be between 90-100%.  
Cloning and plasmids. For pGL3-3′UTR 
reporters, the following 3’UTR fragments of 
TLR4 (NM_138554.3):   TLR4-I (3096-3736),  
TLR4-II (4588-5000), TLR4-III (5028-5384) and 
CD80 (NM_005191.3.) (2184-2525) were PCR 
amplified, digested with FseI (New England 
Biolabs) and XbaI (Fermentas) and inserted 
downstream the LUC coding region into the same 
restriction sites of pGL3-Control (Promega). The 
amplification primer sequences are available in 
Supplementary methods. The cloned plasmids 
were verified by sequencing, ARE plasmid was a 
kind gift of S. Vasudevan and is published before 
(12). The cloning primers: TLR4-I: Forward: 
ATATCTAGAAAAGACAGAG AAAACAGAA 
AGAGACA, Reverse: ATAGGC CGGCCTTCC 
TTCCTGCCTCTAGCCC; TLR4-II: Forward: 
ATATCTAGACCCGGAGGCCATTATGCTAT, 
Reverse: ATAGGCCGGCCCA ATTTGATGAG 
TTTAGACATAGTCAC; TLR4-III:  Forward: 
ATATCTAGAATATCAATTATGTCTGAA TG 
AAGCTAT, Reverse: ATAGGCCGGCCAG 
AGAACTCATCTCAAACAGCC; CD80 
Forward: ATATCTAGACCATAGGGCCTCCT 
TAGATCCC, Reverse: ATAGGCCGGCCGCA 
A GGTTTGTGAAGCAGCA 
Luciferase assays. 8 × 104 HEK293 cells were 
plated into 24-well plates and transfected after 24 
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h with 20 ng of renilla encoding pRL-TK 
(Promega), 100 ng pGL3-3’UTR reporters  and 
either with 50 nM pre-miR-511 precursor or the 
FAM labeled pre-miR-control (Applied 
Biosystems) using siPORT NeoFX Transfection 
Agent (Applied Biosystems). Cells were 
harvested either after 48h or 96h in contact 
inhibition conditions (13) and analysed using 
Promega dual luciferase assay. Luminescence 
was counted with Wallac 1420 (Perkin Elmer). 
Western analysis and FACS. For Westerns, 
rabbit polyclonal anti human TLR4, (sc-10741, 
Santa Cruz Biotec) in 2% milk, mouse 
monoclonal anti human GAPDH (ab8245, 
Abcam), mouse monoclonal hnRNPU (ab10297 
Abcam) and DICER1 (ab14601 Abcam) in 5% 
milk were used. Signals were detected with the 
ECL Advance Western Blotting Detection Kit 
(GE Healthcare) and captured and quantified by 
ImageQuantTM-RT ECL image analysis system. 
For FACS, fluorescence conjugated antibodies 
CD83, DC-SIGN, CD86 (BD Biosciences), CD14 
and HLA-DR (Miltenyi Biotec) and 
FACSCalibur (BD Biosciences) were used. Data 
were analyzed and visualized with FlowJo v. 7.6. 
RNA purification and quantitative RT-PCR. 
RNA was purified using Trizol (Invitrogen) and 
when needed, further purified with RNAeasy 
Mini Kit (Qiagen). To maintain small RNA 
fraction, 3.5 volume of 100% ethanol was added 
to the samples before loading on Qiagen mini 
columns. Alternatively, miRNAeasy Mini Kit 
(Qiagen) was used. The concentration and quality 
of RNA was assessed with NanoDrop ND-1000 
spectrophotometer and Agilent RNA 6000 Nano 
Kit on Agilent 2100 Bioanalyzer. For mRNA RT-
PCR, cDNA from 200 ng of total RNA was 
synthesized using oligo-dT and SuperScript III 
Reverse Transcriptase (Invitrogen). PCR was 
carried out with Maxima SYBR green/Rox 
Master Mix (Fermentas). miRNA expression was 
analyzed using Taqman MicroRNA Assays, 
TaqMan MicroRNA Reverse Transcription Kit 
(Applied Biosystems) and 5X HOT FIREPol 
Probe RT-PCR Mix Plus (Solis Biodyne). All 
RT-PCRs were carried out on ABI Prism 7900, 
the relative gene expression levels were 
calculated using the comparative Ct (∆∆Ct) 
method (Applied Biosystems). The RT-PCR 
primers were the following:  DICER: Forward: 
GGCTGTAAAGTACGACTACC Reverse: 
GATCTCCTAAGCTCAGAATCC; TLR4-1 
Forward: ATCCCCTGAGGCATTT AGGC, 
Reverse: TCAATTGTCTGGATTTCAC 
ACCTG; TLR4-2 Forward: TCCCTCCCCT 
GTACCCTTCT, Reverse: AGCATTGCCCA 
ACAGGAAAC; TLR4-3 Forward: ATCCCT 
GGGTGTGTTTCCAT, Reverse: TGCGGAC 
ACACACACTTTCA, HPRT, Forward: GACT 
TTGCTTTCCTTGGTCAGG, Reverse: AGTC 
TGGCTTATATCCAACACTTCG 
RNA profiling and miRNA target prediction. 
miRNA profiling was carried out on Illumina 
miRNA Universal-16 BeadChips (miRBase 
version 12.0) and mRNA profiling by Illumina 
Human-6 v2 BeadChips in Core Facility at 
Department of Biotechnology, University of 
Tartu. The data were analyzed with BeadStudio 
Gene Expression Module v3.3.7 (Illumina) using 
Average Normalization for miRNA data and 
Illumina’s custom rank invariant method for 
mRNA arrays. Genes with differential expression 
p-value <0.05 were considered differentially 
expressed. Further analyses and visualizations 
were carried out using Microsoft Excel and Multi 
Experiment Viewer 4.0. Unsupervised 
hierarchical clustering was done using Euclidean 
distance and average linkage analysis. The 
miRNA and mRNA microarray data are available 
at ArrayExpress as E-TABM-968 and E-TABM-
976, respectively. The compiled miRNA target 
lists were generated based on Diana microT 
(v3.0), miRanda  (downloaded in September 
2008), PicTar (downloaded in August 2009), 
rna22 (downloaded in August 2009), Targetscan 
conserved targets (5.1) 
 
RESULTS 
 
 Updated miRNA profile of human DCs and 
MFs. Human blood derived MOs were 
differentiated into DCs and MFs as described 
earlier (4) and stimulated on day 6 with LPS, as 
TLR4 ligand, or curdlan, as Dectin-1 (CLEC7A) 
ligand. Flow cytometric analysis showed well-
established phenotype of immature DCs (DC-
SIGN+CD14−) and MFs (DC-SIGN−CD14+) on 
day 6 (Fig. S1A, left panels). Following 
stimulations, DCs had significantly higher 
expression of CD86, HLA-DR (MHCII) and 
CD83. For activated MFs, enhancement of CD86 
and CD83 was detected (Fig. S1A, histograms). 
Consistent with the previous studies (4, 16, 18, 
19, 23, 27, 31), the expression of miR-155 and 
miR-146a was strongly induced in response to 
LPS and curdlan both in DCs and MFs but the 
expression of miR-132 was mainly induced 
during the differentiation phase (Fig. S1B).   
 Next, total RNA from 2 or 3 different donors 
for each condition was analyzed on Illumina 
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miRNA arrays containing probes for 858 human 
mature miRNAs based on miRBase 12.0 
(32)(Fig. 1A). Altogether, 307 to 380 miRNAs 
with detection p-value<0.05 were found to be 
expressed in analyzed cells populations, whereas 
almost half of the detected miRNAs had 
relatively high signal intensities (Table S1). 
Compared with MOs, 39 miRNAs were up-
regulated and 10 were down-regulated with 
differential p-value<0.05 in immature or mature 
DCs and MFs (Fig. 1A, Table S2). miR-99b, 
miR-212 and miR-511 were detected as the three 
most highly up-regulated miRNAs both in DCs 
and MFs. Some miRNAs, for instance miR-193b, 
miR-125b and miR-99a, were preferentially 
expressed in DCs, whereas miR-139-5p, miR-1 
and miR-218 had higher expression in MFs. 
Hierarchical clustering showed that according to 
miRNA expression pattern, MOs are more similar 
to MFs than DCs (Fig. S2). Changes in miRNA 
expression were found to occur mainly during the 
differentiation. After stimulation, relatively mild 
increased expression was detected for 16 
miRNAs. No miRNAs specific for either LPS or 
curdlan stimulation was detected (Table S3). 
Consistently to quantitative RT-PCR results 
carried out during the initial cell differentiation 
verification, miRNAs miR-146a and miR-132 
were detected as differentially regulated. 
However, for miR-155, we could not detect 
statistically significant expression change on the 
Illumina arrays (Fig. 1SB and 1A). 
 To further verify Illumina array results, we 
carried out quantitative RT-PCR for 12 selected 
miRNAs, which confirmed that miR-193b and 
99a were the most highly up-regulated in DCs 
and miR-511, miR-99b and miR-212 in both DCs 
and MFs (Fig. 1B, Fig. S3, Table S4). In 
conclusion, we have described updated miRNA 
expression profiles of human blood MOs and MO 
derived immature and mature DCs and MFs and 
found several miRNAs, including the most highly 
up-regulated miR-511 and DC specific miR-
193b, not reported in these cells earlier.  
siRNA knock-down of DICER1 and inhibition 
of up-regulated miRNAs results in reduced DC-
SIGN expression. To further prove that miRNAs 
are essential for DC differentiation, we carried 
out siRNA knock-down of DICER1, a protein 
that is indispensable for miRNA processing (33). 
DCs were differentiated in the presence of control 
siRNAs or two different siRNAs and s23754 
s23756 for DICER1. Better knock-down 
efficiency of DICER1 was achieved with s23754, 
typically about 50% on both mRNA and protein 
level (Fig. 2A and 2B), and this inhibition caused 
lower DC-SIGN and higher CD14 protein levels 
(Fig. 2C), which is an indication of delayed 
maturation phenotype in DCs. To further analyze 
the effect of DICER1 knock-down on DC 
differentiation, the DC-SIGN/CD14 ratios from 
four experiments carried out on cells from 
different donors were calculated and found to be 
significantly different (Fig. 2D).  
Next, we performed ex vivo DC 
differentiation in the presence of sequence 
specific miRNA inhibitors for miR-511 and miR-
99b, as the two most highly up-regulated 
miRNAs in both DCs and MFs, and for DC 
specific miR-193b (Fig. 1A and B, Table S2). 
The transfection of miRNA inhibitors resulted in 
50-90% reduced expression of specific miRNA if 
measured by RT-PCR (Fig. 2E), which led to 
reduced DC-SIGN protein levels, if the inhibitors 
for miRNA-511 and miR-99b were used (Fig. 
2F). The levels of CD14 and HLA-DR surface 
markers were not influenced by specific miRNA 
inhibitors (data not shown). In conclusion, the 
data from DICER1 knock-down and specific 
miRNA inhibition experiments show that 
miRNAs in general and miR-511 and miR-99b in 
particular have impact on DC-SIGN expression, 
and thus, presumably also on DC differentiation.  
Up-regulated miRNAs potentially target 
genes with immune function. Next, we searched 
the potential targets for miR-511, miR-99b and 
miR-193b. Studies on miR-181 and miR-223 
involving different computational and 
experimental approaches have shown that 
different programs have overall similar target 
prediction capability. However, the top third 
TargetScan predictions have been shown to 
correlate significantly better with protein down-
regulation than predictions of the other programs 
or the bottom third of TargetScan predictions (34, 
35). Thus, we first selected all TargetScan 
predicted targets with total context score <-0.2 
corresponding to the top one third of the lists. To 
search for immunologically important targets, we 
only included 4274 human genes related to 
immune function according to Immport Database 
(https://www.immport.org). As another approach, 
we compiled lists of potential targets based on 5 
different algorithms: Targetscan 5.1(36), 
Miranda(37), DIANA-microT(38), Pictar(39) and 
rna22(40). The putative targets were ranked by 
their position in any of the input lists, the top 500 
genes from this ranking were used in subsequent 
analysis. Genes with very low expression, 
average signal intensity < 50 based on the 
4 
 
 at H
auptbibliothek Universitaet Zuerich Irchel. Bereich Forschung, on M
arch 5, 2012
w
w
w
.jbc.org
D
ow
nloaded from
 
Illumina mRNA expression data (E-TABM-976), 
were excluded. The remaining working lists, 
containing 135 - 247 targets per each studied 
miRNA, were analyzed using the g:GOSt tool at 
g:Profiler website (http://biit.cs.ut.ee/gprofiler/) 
that retrieves most significant Gene Ontology 
(GO) terms, KEGG and REACTOME 
pathways(41). According to this search, miR-511 
showed the greatest potential to target several 
pathways important for DC and MF 
differentiation, maturation and functions (Table 
1).  
Expression of miR-511 accompanies with the 
enhanced level of the TLR4 protein in 
differentiating DCs. Among the Targetscan 
predictions, TLR4 was found to be one of the best 
scored (3 target sites, context score -0.89) of 
miR-511 targets expressed in DCs. Thus, we next 
studied whether TLR4 mRNA and protein levels 
are influenced by miR-511. We first followed 
miR-511 and TLR4 expression during the DC 
differentiation. Since the TLR4 primary transcript 
has got four different alternative polyadenylation 
signals, we designed three different primer sets to 
analyze the levels of alternatively polyadenylated 
TLR4 mRNAs separately. TLR4-1 recognized all 
possible TLR4 transcripts, TLR4-2 and TLR4-3 
only the transcripts with longer 3’UTRs 
containing 2 or 3 possible miR-511 target sites, 
respectively (Fig. 3A, Fig. S4). As shown on Fig. 
3B, the miR-511 level is gradually enhanced 
during the differentiation from day 1 to day 6, 
whereas the DC-SIGN mRNA level is even 
higher during the first days if compared with DCs 
of the later time points (Fig. 3B, left panel). 
Although the amount of longer TLR4 transcripts 
seemed to be reduced during the differentiation, 
the total amount of TLR4 mRNA was relatively 
constant until DC6 (Fig. 3B, right panel) and the 
TLR4 protein level was gradually enhanced up to 
3.4 times in comparison to MOs (Fig. 3C). We 
next studied whether reduction of the longer 
TLR4 transcripts can occur because of the 
presence of multiple miR-511 sites and whether 
there is difference in accumulation of the TLR4 
protein when miR-511 is inhibited (Fig. 3D). 
Interestingly, the TLR4 protein levels were about 
2 fold higher in control-transfected cells in 
comparison with miR-511 inhibited samples on 
day 4 and day 6 of the differentiation when more 
miR-511 had accumulated into the cells (Fig. 3D 
and 3E). No significant difference was detected in 
TLR4 mRNA different transcript levels in miR-
511 knock-down samples in comparison to the 
control transfections (Fig. 3F). Also, the knock-
down of miR-511 did not lead to major changes 
in main DC activation markers CD86 and CD80 
and maturation marker CD83 upon LPS 
stimulation measured by FACS (Fig. S5A), 
although reduction of the TLR4 protein was 
detected in LPS stimulated DCs when miR-511 
was inhibited (Fig. S5B-D). These data together 
show that there is correlation between high 
expression of miR-511 and enhanced level of the 
TLR4 protein, which suggested that miR-511 is a 
positive regulator of the TLR4 protein translation 
in MO derived DCs. 
miR-511 has versatile influence on its 
putative targets TLR4 and CD80 in luciferase 
assays. We next studied whether TLR4 is 
targeted by miR-511 in luciferase (LUC) reporter 
assays. Since TLR4 contains polyadenylation 
signals between each potential miR-511 target 
sequence, three different fragments of TLR4 
3’UTR were inserted downstream the LUC 
coding region into the pGL3-contr vector. In 
addition, we cloned the 3’UTR fragment of CD80 
containing two putative miR-511 target sites. 
Next, the LUC-3’UTR reporters were transfected 
either alongside with pre-miR-511 or the control 
pre-miRNA into the HEK293 cells. It has been 
shown that in cell cycle arrested conditions 
miRNAs can up-regulate the translation (12, 13). 
Since human blood MOs do not proliferate during 
the differentiation, and since we observed 
positive correlation of miR-511 expression and 
the TLR4 protein level in differentiating DCs, we 
carried out LUC assays at both 48 and 96 hours 
after the transfection, thus in normal conditions 
and in contact inhibited cells where cells are 
arrested in G0 phase (13). Fig. 4A shows that 
during normal growth conditions, the expression 
of the LUC constructs with 3’UTR fragments 
containing the first and second predicted TLR4 
target sites of miR-511 (TLR4 I and TLR4 II) and 
3’UTR fragment of CD80 containing two miR-
511 target sites were down-regulated in the 
presence of miR-511 when compared with the 
levels of control transfected cells. No significant 
influence on the control vector or constructs 
containing TLR4 III site was detected (Fig. 4A). 
Interestingly, in contact inhibited cells, in the 
presence of transfected miR-511, the LUC 
expression levels for TLR4 I, TLR4 II and CD80 
were not higher and for TLR4 III construct, the 
LUC expression was even significantly enhanced 
when compared to the control transfected cells. 
The expression of the ARE plasmid used as a 
positive control for cell cycle arrest was enhanced 
in contact inhibited cells when compared with the 
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control plasmid (Fig. 4B). These data together 
indicate that miR-511, depending on the target 
mRNA 3’UTR and cellular environment, can 
either up- or down-regulate the target gene 
expression. 
 
 
DISCUSSION 
 
Ex vivo differentiated human blood MO 
derived DCs and MFs are excellent experimental 
models to study differentiation and functions of 
MO-DC cell lineage. In addition, MO derived 
DCs are the most common type of DCs used in 
immunotherapeutic approaches (6, 7). In this 
study, we first describe updated miRNA 
expression profiles of human blood MO derived 
immature and mature DCs and MFs. Consistent 
with previous studies  (23, 27, 31, 42, 43), we 
found that these cell types have distinct miRNA 
expression profiles and detected several novel 
strongly upregulated miRNAs, including miR-
511. For the activation and maturation of MFs 
and DCs, we used LPS and curdlan, as ligands for 
TLR4 and Dectin-1, respectively, both leading to 
activation through the NF-κB pathway (44-46). 
Concordantly, very similar miRNA expression 
changes were seen for both inductions, whereas 
we could not find any novel highly expressed and 
substantially up-regulated endotoxin dependent 
miRNA. We also could not detect miR-155 
among LPS stimulated genes from Illumina array, 
while its upregulation was obvious by RT-PCR. It 
is possible that up-regulation of miR-155 after 
LPS stimulation occurs on RNA processing level, 
since the RT-PCR with Taqman probes detects 
only mature miRNAs, while the Illumina arrays 
might also recognize miRNA precursors.  
Further, knock-down of DICER1 with 
siRNAs led to lower expression of DC-SIGN and 
higher level of monocyte marker CD14 
confirming that miRNAs in general are needed 
for proper differentiation of  DCs. Similarly, 
specific inhibition of miR-511 and miR-99b 
resulted in reduction of DC-SIGN indicating that 
these two miRNAs influence DC differentiation. 
Previously, Hashimi et al. have shown that 
inhibition of number of miRNAs, including miR-
99b, influences MO derived DC differentiation. 
However, based on data from three donors, they 
found that only inhibition of miR-34a had 
statistically significant impact. Similarly to our 
study, the extent of influence of specific miRNA 
inhibitors was variable in cells from different 
donors (27) which indicates that differences exist 
in the complicated miRNA expression network in 
each individual.  
The regulation by miRNAs mainly occurs via 
pairing of miRNA 6-8 nt seed sequences to the 
target mRNA (35). Therefore, prediction of true 
miRNA targets by computational approaches has 
been a challenge. According to the two 
approaches used in this study, we found many 
genes from ontology groups and pathways with 
immune functions to be overrepresented among 
miRNA-511 potential targets. Interestingly, miR-
511-1 and miR-511-2 genes themselves are 
located within the fifth intron of mannose 
receptor gene MRC1 and its very recent human 
specific copy MRC1L, respectively. Therefore, 
expression of miR-511 is most probably regulated 
coordinately with MRC1 genes, which are only 
expressed in MFs, some DCs and subsets of 
vascular and lymphatic endothelial cells (47). In 
this study, we examined the possible impact of 
miR-511 to its proposed targets TLR4 and CD80. 
Interestingly, we found that miR-511 knock-
down results in enhanced TLR4 protein levels in 
differentiating DCs. However, we could not 
detect consistent influence of miR-511 knock-
down to DC activation markers CD86 and CD80 
as well as to maturation marker CD83 (Fig. S5). 
It is possible that in other cells types or in certain 
disease conditions miRNA-511 impact is more 
obvious.  
It has been shown that in the cell cycle arrest 
at G0 phase, certain miRNAs can enhance the 
target protein levels (12, 13). The alternative 
possibility would be that miR-511 competes with 
any more strong degradation factor, as it has been 
recently shown for miR-466, which replaces TTP 
protein and therefore stabilizes IL10 mRNA (48). 
In some cases, the mechanism of uncommon 
expression enhancement effect is not clear as it is 
for miR-155 which has stabilizing influence on 
the TNF-alpha mRNA in alcohol-treated 
MFs(49). Still, the influence of miR-511 on 
TLR4 protein expression seems to be direct since 
in HEK293 cells either reduced LUC levels in 
normal conditions for TLR I and II or enhanced 
LUC level for TLR III in contact inhibited cells 
were determined in the presence of miR-511. In 
addition, although human MOs can be 
differentiated in tissue culture conditions, they do 
not proliferate, and thus, they are cell cycle 
arrested.  Even though it is generally accepted 
that many partially and fully differentiated 
immune cells are quiescent or arrested in 
G0/resting phase, only limited number of studies 
about their entering and leaving from this state 
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are available. Previously has been demonstrated 
that differentiation of functional DCs from human 
blood derived MOs depends on expression of p21 
encoded by CDKN1A gene, which is considered a 
hallmark of G1 phase (50). According to the 
mRNA array analysis we performed, p21 is also 
up-regulated during the DC differentiation. The 
p27 encoding gene CDKN1B, a hallmark of G0, 
however, is slightly down-regulated on day 6 of 
DC differentiation in comparison to MOs. After 
the stimulation with LPS, it is up-regulated again 
(E-TABM-976). The similar expression pattern of 
p27 is confirmed in protein level by a very recent 
study, which also suggests that miR-221 has 
influence on p27 protein level in differentiating 
DCs (51). Our data, the miR-511 inhibition 
results in differentiating DCs and the LUC 
reporter assays in proliferating and contact 
inhibited HEK293 cells, indicate that regulation 
of TLR4 by miR-511 can also depend on cell 
cycle. Further studies are needed to better 
understand the influence of miR-511 and 
miRNAs in general in distinct cellular conditions. 
 In conclusion, we have determined updated 
miRNA expression profiles for human blood 
MOs, DCs and MFs and have found miR-511 as 
highly expressed MF and DC specific miRNA 
with strong immune regulatory potential. In 
addition, our data highlight that influence of 
miRNAs can be modulated by cellular 
environment.  
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error of the mean 
 
 
 
FIGURE LEGENDS 
 
Figure 1. MOs, DCs and MFs have distinct miRNA expression profiles. (A) Heatmaps of miRNAs 
that are up- or down-regulated (differential p-val<0.05) in DCs and/or MFs if to compare with the 
levels in MOs. The miRNAs, which are shown, have an average expression level of over 100 
in at least one condition. Each column represents expression levels of miRNA (shown right) in each 
sample (shown above). Log2 expression values for each miRNA are mean-centered across all the 
analyzed miRNA expression values. Color scale from green (lower) to red (higher) represents 
deviation from the mean (black). (B) Verification of Illumina array results with RT-PCR for four 
example miRNAs. Data from one representative donor are shown and are normalized to the value in 
MOs (=1). 
 
Figure 2. Reduced expression of DICER1 and selected miRNAs results in down-regulation of DC 
specific surface marker DC-SIGN. (A) Inhibition of DICER1 (si-DICER) is shown as average 
mRNA expression level with SEM of three different treatment normalized to average of the negative 
controls (=1, si-neg). (B) Western analysis of differentiating DCs treated with control DICER1 siRNA. 
Data are normalized to the hnRNPU, the numbers indicate the fold difference compared to the control 
transfection (=1). (C, D) FACS analysis of DCs treated with either si-DICER or control siRNAs. (C) 
Histograms represent the geometric mean fluorecent intensities of indicated surface molecules shown 
as % of maximum in DICER1 siRNA treated cells (filled gray) relative to control treated cells (black 
line). (D) Ratios of DC-SIGN and CD14 MFI values were calculated and are shown relative to the 
control transfections (neg, =1), data from four different donors are blotted, p-value is calculated using 
Mann-Whitney test.  (E) Inhibition of individual miRNAs are shown as average miRNA expression 
level with SEM of three different treatment normalized to the average levels of control transfections 
(=1, neg). (F) FACS analyses of DCs treated with indicated miRNA inhibitors. Geometric MFIs were 
normalized to control transfected cells (=1,  neg) and are presented as Relative fluorecence intensities 
(FI), data from 5 different donors are blotted, p-values are calculated using Mann-Whitney test. 
 
Figure 3. Expression of miR-511 correlates with the enhanced level of the TLR4 protein in 
differentiating DCs. (A) Schematic of the TLR4 mRNA transcript containing miR-511 target sites, 
alternative polyadenyation sites and positions of RT-PCR primers (designated with arrows). (B) The 
RNA expression levels of miR-511, DC-SIGN and TLR4 transcripts in differentiating DCs. Data are 
one representative out of three independent experiments. RT-PCR of specific genes are normalized 
either to HPRT or let-7a and the expression levels in MOs (=1). (C, E) Western analysis of TLR4 in 
differentiating DCs (C) and in the presence of miR-511 inhibitor (anti-511) or the control inhibitor 
(neg) (E) are normalized to the GAPDH, the numbers indicate the fold difference compared to the 
MOs (=1, C) or control transfected cells on day 2 (DC2, neg, E). (D) Inhibition of miR-511 is shown 
as average miRNA expression level with SEM of two parallel treatment normalized to the levels of 
control transfection on day 2 (DC2, neg, =1). 
 
Figure 4. The influence of miR-511 to expression of its proposed targets in luciferase reporter 
assays. (A, B) The luciferase (LUC) activity was measured either 48 (A, normal conditions) or 96 (B, 
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contact inhibited conditions ci) hours after the transfection of the LUC reporters and pre-miR-511 or 
the control pre-miRNA. Data are mean with SEM of at least eight different transfections. All data are 
normalized to Renilla and the LUC values of control transfections (=1). LUC activity measurements of 
the ARE reporter used as positive control were done 48 hours (norm, =1) and 96 hours (ci) after the 
transfections and are normalized to Renilla and the levels of pGL3-control. Three different target 
sequences of TLR4 are cloned in separate LUC constructs and are designated as TLR4 I, II and III. P-
vaues are calculated using Mann-Whitney test. 
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Table 1. DC and MF specific miRNAs potentially target genes from functional pathways or 
groups important in the differentiation or immune functions  
miRNA 
Nr of 
targets 
Functional group and nr of 
genes   ID   
Putative targets in functional 
group Significanceb Methoda 
miR-511 
135 
Toll-like receptor 
signaling pathway 
107 
KEGG:04620
TLR4 STAT1 CD80 
MAP3K7IP2 CD86 IRAK1 
MAP3K7 TIRAP 2.56E-05 T 
myeloid cell 
differentiation 
93 
GO:0030099 
BCL6 IRF4 PPARG JAK2 
SMAD5 TIRAP 4.11E-05 T  
JAK-STAT cascade 47 GO:0007259 
NLK STAT1 SOCS2 JAK2 
STAT5A SOCS6 STAT4 2.84E-08 T  
regulation of interleukin-
2 production 
28 
GO:0032663 
IRF4 CD80 CD86 STAT5A 
MAP3K7 1.16E-06 T  
regulation of 
transcription from RNA 
polymerase II promoter 
732 
GO:0006357 
HIPK2 TIAL1 EP300 RYBP 
BCL6 AHR YY1 HDAC2 
IRF4 PPARG STAT5A SRF 
SMAD5 IRF2 VHL LITAF 3.73E-05 T  
193 
negative regulation of 
gene expression 
497 
GO:0010629 
ATBF1 CBX1 DEDD DEDD2 
GABPA NAB2 ORC2L 
POU2F1 RUNX2 RYBP 
SATB2 SIN3A ZNF281 
TARBP2 TGIF1 TNRC6B 2.29E-05 C 
miR-
193b 234/247 
Chemokine signaling 
pathway 
189 
KEGG:04062 CRK CRKL KRAS SOS2 1.56E-06 T  
Chronic myeloid 
leukemia 
76 
KEGG:05220
CRKL CCND1 BCL2L1 
RUNX1 CRK KRAS 5.23E-04 C 
miR-99b 225 
beta-catenin binding 
27 
GO:0008013 
NUMB DVL3 SMAD7 
C5ORF22 AXIN1 8.49E-06 C 
Pathways in cancer 
334 
KEGG:05200
AXIN1 BID CBL CDK6 
DVL3 FZD1 HSP90B1 IGF1R 
IKBKG ITGB1 STAT5B 7.03E-04 C 
a The target lists used for analysis were generated either based on top third of Targetscan (T) or by 
compiling five different algorythms, Targetscan 5.1 , Miranda, DIANA-microT, Pictar and rna22, 
predictions (C).  
bThe p-value form Fisher exact test showing the significance of the overlap between the target list and 
indicated functional category. 
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Fig. 1. MOs, DCs and MFs have distinct miRNA expression profiles.
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Fig. 2. Reduced expression of DICER1 and selected miRNAs results in downregulation of DC specific 
surface marker DC‐SIGN. 
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Fig. 3. Expression of miR‐511 correlates with the enhanced level of the TLR4 protein in differentiating 
DCs 
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Fig. 4. The influence of miR‐511 to expression of its proposed targets in LUC reporter assays. 
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